Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end

Karyopharm Therapeutics Inc.

2024-Q2 EPS reported -$0.48 revenue$75,912,000

Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).
Net income $23.8M ($0.15 basic EPS) vs net loss $32.6M in Q2 2023; includes $44.7M non-cash gain on debt extinguishment.
Raises FY2024 total revenue guidance low end to $145M from $140M; lowers R&D/SG&A expense guidance to $250-265M from $260-280M.
Phase 3 SENTRY (myelofibrosis) top-line data on track for 2H 2025; XPORT-EC-042 (endometrial) top-line delayed to early 2026 due to screen failures.
Debt refinancing extended majority of maturities to 2028/2029; cash $152.5M; cash runway into Q1 2026 (excl. $49.5M debt payments).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.